A Rare Variant in the Osteoarthritis-associated Locus GDF5 is Functional and Reveals a Site That Can Be Manipulated to Modulate GDF5 Expression
Overview
Affiliations
Osteoarthritis (OA) is a polygenic disease characterized by cartilage loss, with the single-nucleotide polymorphism (SNP) rs143383 (C/T) influencing OA susceptibility across a range of ethnic groups. The SNP resides within the 5'-UTR of the growth and differentiation factor 5 gene (GDF5), with the OA-associated T-allele mediating reduced GDF5 expression. As GDF5 codes for a cartilage anabolic protein, this reduced expression may explain why the T-allele of rs143383 is an OA risk factor. Our deep sequencing of GDF5 identified a C/A transversion located -41 bp relative to the gene's transcription start site. This promoter variant is predicted to affect transcription factor binding and it may therefore highlight a regulatory site that could be exploited to manipulate GDF5 expression and alleviate the detrimental effect mediated by the T-allele of rs143383. Here, we describe our functional assessment of the -41 bp variant. Using reporter constructs we demonstrated that the transversion leads to increased gene expression to such a degree that the A-allele is able to compensate for the reduced expression mediated by the T-allele of rs143383. Using electrophoretic mobility shift assays we identified YY1 as a trans-acting factor that differentially binds to the alleles of the -41 bp variant, with more avid binding to allele A. Knockdown of YY1 led to a significant reduction in GDF5 expression, supporting YY1 as a GDF5 activator. In conclusion, we demonstrated that the -41 bp variant is functional and we have identified a regulatory region of GDF5 that can be exploited to overcome the OA genetic deficit mediated by the T-allele of rs143383.
Fox S, Waskiewicz A Front Cell Dev Biol. 2024; 12:1338070.
PMID: 38385025 PMC: 10879340. DOI: 10.3389/fcell.2024.1338070.
Joint disease-specificity at the regulatory base-pair level.
Muthuirulan P, Zhao D, Young M, Richard D, Liu Z, Emami A Nat Commun. 2021; 12(1):4161.
PMID: 34230488 PMC: 8260791. DOI: 10.1038/s41467-021-24345-9.
Growth differentiation factor 5 in cartilage and osteoarthritis: A possible therapeutic candidate.
Sun K, Guo J, Yao X, Guo Z, Guo F Cell Prolif. 2021; 54(3):e12998.
PMID: 33522652 PMC: 7941218. DOI: 10.1111/cpr.12998.
The GDF-5 mutant M1673 exerts robust anabolic and anti-catabolic effects in chondrocytes.
Mang T, Kleinschmidt-Dorr K, Ploeger F, Lindemann S, Gigout A J Cell Mol Med. 2020; 24(13):7141-7150.
PMID: 32497388 PMC: 7339174. DOI: 10.1111/jcmm.15149.
Mohasseb D, Saba E, Saad N, Sarofeem A Mediterr J Rheumatol. 2020; 30(2):114-122.
PMID: 32185351 PMC: 7045969. DOI: 10.31138/mjr.30.2.114.